瑞巴派特联合法莫替丁治疗早期胃癌术后溃疡患者临床研究  

Clinical trial of rebamipide combined with famotidine in the treatment of postoperative ulcer in patients with early gastric cancer

作　　者：王锐[1] 李多[1] 彭昭[1] WANG Rui;LI Duo;PENG Zhao(Department of Gastroenterology,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075100,Hebei Province,China)

机构地区：[1]河北北方学院附属第一医院消化内科,河北张家口075100

出　　处：《中国临床药理学杂志》2024年第14期2008-2012,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的分析瑞巴派特胶囊联合法莫替丁片治疗早期胃癌术后溃疡患者的临床价值。方法选取早期胃癌术后溃疡患者作为研究对象,按照治疗方案用队列法分为对照组和试验组。对照组口服法莫替丁片20 mg,bid;在对照组治疗的基础上,试验组口服瑞巴派特胶囊0.1 g,tid,2组均持续治疗4周。对比2组患者胃黏膜形态学指标、胃肠激素[血管活性肠肽(VIP)、胆囊收缩素(CCK)、胃动素(MTL)]、胃蛋白酶原[胃蛋白酶原Ⅰ(PG I)、胃蛋白酶原Ⅱ(PGⅡ)]。结果对照组和试验组各入组40例。治疗后,试验组的总有效率92.50%(37例/40例)较对照组高[75.00%(30例/40例)],在统计学上差异有统计学意义(P<0.05)。治疗后,试验组和对照组的黏膜厚度评分分别为(0.22±0.08)和(0.51±0.10)分,炎性细胞浸润程度评分分别为(0.42±0.08)和(0.79±0.16)分,腺体密度评分分别为(0.80±0.12)和(1.16±0.27)分,黏膜形态评分分别为(0.48±0.11)和(0.74±0.12)分,VIP分别为(16.78±2.49)和(19.46±3.02)ng·L^(-1),CCK分别为(55.38±58.47)和(71.48±10.38)ng·L^(-1),MTL分别为(82.19±14.52)和(97.68±11.58)pg·mL^(-1),PG I分别为(168.74±17.42)和(136.78±15.44)ng·mL^(-1),PGⅡ分别为(16.42±2.50)和(20.58±3.79)ng·mL^(-1),试验组的上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05)。试验组药物的不良反应发生率[15.00%(6例/40例)]与对照组[10.00%(4例/10例)]比较,在统计学上差异无统计学意义(P>0.05)。结论瑞巴派特胶囊联合法莫替丁片治疗早期胃癌术后溃疡患者有效性和安全性佳,可改善患者胃黏膜形态学指标、胃肠激素及胃蛋白酶原。Objective To analyze the clinical value of rebabapide combined with famotidine in the treatment of postoperative ulcers in patients with early gastric cancer.Methods Postoperative ulcer patients with early gastric cancer were selected as the study objects,and were divided into control group and treatment group according to treatment plan using cohort method.Control group was orally treated with famotidine tablet 20 mg,bid;on the basis of the control group,the treatment group was orally treated with rebabapide capsule 0.1 g,tid,and both groups were treated for 4 weeks.The gastric mucosal morphological indexes,gastrointestinal hormone[vasoactive intestinal peptide(VIP),cholecystokinin(CCK),motilin(MTL)],pepsinogen[pepsinogenⅠ(PGⅠ),pepsinogenⅡ(PGⅡ)]in the two groups were compared.Results There were 40 patients in the treatment group and control group.After treatment,the total clinical effective rate of the treatment group was 92.50%(37 cases/40 cases)and higher than that of the control group[75.00%(30 cases/40 cases)],and the difference was statistically significant(P<0.05).After treatment,the scores of mucosal thickness in treatment group and control group were(0.22±0.08)and(0.51±0.10)points;the scores of inflammatory cell infiltration degree were(0.42±0.08)and(0.79±0.16)points;the scores of gland density were(0.80±0.12)and(1.16±0.27)points,respectively;mucosal morphology scores were 0.48±0.11 and 0.74±0.12;VIP were(16.78±2.49)and(19.46±3.02)ng·L^(-1);CCK were(55.38±58.47)and(71.48±10.38)ng·L^(-1),respectively;MTL were(82.19±14.52)and(97.68±11.58)pg·m L^(-1);PGⅠwere(168.74±17.42)and(136.78±15.44)ng·m L^(-1),respectively;PGⅡwere(16.42±2.50)and(20.58±3.79)ng·m L^(-1),respectively.Compared with control group,there were statistically significant differences in the above indexes in treatment groups(all P<0.05).The incidence of adverse drug reactions in the treatment group was 15.00%(6 cases/40 cases)compared with 10.00%(4 cases/10 cases)in the control group,there was no statistical sig

关 键 词：瑞巴派特胶囊 法莫替丁片 胃溃疡 早期胃癌术后 

分 类 号：R975[医药卫生—药品]